# Primus Pharmaceuticals clinical trials: 21 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Primus Pharmaceuticals as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Primus Pharmaceuticals: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/primus-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07932613 | Effect of Metaxalone 640 mg (M640) on Driving, Cognition, and EEG Dynamics Compared to Tizanidine 8 mg in Adults | Primus Pharmaceuticals | Phase 4 | Not yet recruiting | Healthy Participant | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932613) |
| September 3, 2026 | NCT07801066 | Testing Healthy Participants for Drowsiness After Single Dosing of Two Different Doses of Muscle Relaxer | Primus Pharmaceuticals | Phase 4 | Recruiting | Healthy Participants | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801066) |
| April 24, 2024 | NCT06382662 | Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition | Primus Pharmaceuticals | Phase 4 | Completed | Cognitive Impairment | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06382662) |
| April 4, 2024 | NCT06348303 | Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg | Primus Pharmaceuticals | Phase 4 | Completed | Healthy Participants | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06348303) |
| February 13, 2024 | NCT06256575 | Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis | Primus Pharmaceuticals | Not applicable | Recruiting | Scleroderma, Systemic, Digital Ulcer | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06256575) |
| December 5, 2023 | NCT06157177 | Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions. | Primus Pharmaceuticals | Phase 4 | Recruiting | Sciatica Acute, Lumbar Spinal Stenosis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06157177) |
| November 15, 2022 | NCT05616962 | Vasculera in Participants With Lipedema | Primus Pharmaceuticals | Not applicable | Completed | Lipedema | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05616962) |
| March 11, 2021 | NCT04793711 | EpiCeram for Skin Protection in Healthcare Workers | Primus Pharmaceuticals | Not applicable | Terminated | Irritant Contact Dermatitis | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04793711) |
| June 7, 2017 | NCT03179605 | Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 | Primus Pharmaceuticals | Phase 2 | Terminated | Psoriasis | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03179605) |
| April 25, 2016 | NCT02749799 | Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis | Primus Pharmaceuticals | Phase 4 | Completed | Plaque Psoriasis | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02749799) |
| February 17, 2016 | NCT02683408 | Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon | Primus Pharmaceuticals | Not applicable | Completed | Raynaud's Disease | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02683408) |
| October 21, 2015 | NCT02582424 | Safety and Efficacy of PDL-0101 in Patients With Hyperlipidemias: a Pilot Study. | Primus Pharmaceuticals | Not applicable | Completed | Hyperlipidemia | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02582424) |
| August 19, 2015 | NCT02527421 | DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis | Primus Pharmaceuticals | Phase 3 | Terminated | Plaque Psoriasis | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02527421) |
| February 11, 2015 | NCT02361437 | Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers | Primus Pharmaceuticals | Not applicable | Withdrawn | Diabetic Ulcers | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02361437) |
| February 25, 2014 | NCT02070965 | DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis | Primus Pharmaceuticals | Phase 2 | Completed | Plaque Psoriasis | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02070965) |
| October 22, 2013 | NCT01967069 | A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis | Primus Pharmaceuticals | Phase 3 | Completed | Psoriasis | 277 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01967069) |
| September 20, 2013 | NCT01947491 | A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis | Primus Pharmaceuticals | Phase 3 | Completed | Psoriasis | 394 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01947491) |
| June 26, 2009 | NCT00928837 | Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee | Primus Pharmaceuticals | Not applicable | Completed | Osteoarthritis | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00928837) |
| November 14, 2008 | NCT00790985 | Efficacy of Flavocoxid 500 mg Compared With Naproxen 500 mg in Subjects With Moderate-severe Osteoarthritis of the Knee | Primus Pharmaceuticals | Not applicable | Completed | Osteoarthritis of Knee | 223 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00790985) |
| February 14, 2007 | NCT00435292 | Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee | Primus Pharmaceuticals | Not applicable | Completed | Osteoarthritis | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00435292) |
| March 15, 2006 | NCT00303017 | Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study | Primus Pharmaceuticals | Not applicable | Completed | Osteoarthritis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00303017) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 2 | 2 |
| Phase 3 | 3 |
| Phase 4 | 6 |
| Not applicable | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 13 |
| Terminated | 3 |
| Recruiting | 3 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Psoriasis | 3 |
| Osteoarthritis | 3 |
| Dermatitis, Irritant | 1 |
| Dermatitis | 1 |
| Scleroderma, Systemic | 1 |
| digital ulcers | 1 |
| Sclerosis | 1 |
| Scleroderma, Diffuse | 1 |
| Osteoarthritis, Knee | 1 |
| Spinal Stenosis | 1 |
| Hyperlipidemias | 1 |
| Raynaud Disease | 1 |
| Cognitive Dysfunction | 1 |
| Lipedema | 1 |
| Diabetes Mellitus, Type 2 | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Transcription services in the United States](https://specstream.ai/data/businesses/transcription-services/united-states)
- [Tiki bars in the United States](https://specstream.ai/data/businesses/tiki-bars/united-states)
- [Telecommunications services in the United States](https://specstream.ai/data/businesses/telecommunications-services/united-states)
- [Sushi restaurants in the United States](https://specstream.ai/data/businesses/sushi-restaurants/united-states)
- [Steakhouses in the United States](https://specstream.ai/data/businesses/steakhouses/united-states)
